Form 4: Capricor CCO Awarded 80,000 Stock Options

Capricor Therapeutics' Chief Commercial Officer Michael T. Maurer received 80,000 stock options with an exercise price of $29.36.

Summary

• Michael T. Maurer, the Chief Commercial Officer of Capricor Therapeutics, was granted 80,000 stock options on May 26, 2026.
• The options carry an exercise price of $29.36 per share.
• The grant follows a standard vesting schedule where 25% of the shares vest after one year, with the remaining 75% vesting monthly over the subsequent 36 months.
• The options include an early exercise feature, allowing the reporting person to purchase shares before they vest, subject to a repurchase option by the company if service terminates.
• The expiration date for these derivative securities is May 26, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative event that confirms the continued involvement and incentivization of the Chief Commercial Officer.

Positives

• Aligns executive compensation with long-term shareholder value through a 10-year option term.
• Includes a four-year vesting period which serves as a retention mechanism for the Chief Commercial Officer.
• The exercise price of $29.36 establishes a clear benchmark for future growth expectations.

Negatives

• Potential for future share dilution of up to 80,000 shares upon exercise.
• The options currently have no immediate cash value to the executive as they are granted at the current market-related exercise price.

Risks

• The options may expire worthless if the stock price does not exceed $29.36 before May 2036.
• Termination of the executive's service prior to full vesting would result in the forfeiture of unvested options or the repurchase of early-exercised shares.

Future Outlook

The grant of equity to the Chief Commercial Officer suggests a focus on long-term commercial growth and executive retention as the company moves toward its 2036 expiration horizon.

Management Comments

• The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time.
• If the reporting person elects to take advantage of the early exercise feature... the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer.

Industry Context

StockSavvy.ai notes that equity-heavy compensation packages are standard in the biotechnology sector to preserve cash while incentivizing leadership to achieve regulatory and commercial milestones that drive share price appreciation.

Comparison to Industry Standards

• A four-year vesting schedule (25% cliff at year one, monthly thereafter) is the standard 'market' structure for U.S. biotech executive grants.
• The 10-year expiration term is consistent with typical incentive stock option (ISO) and non-qualified stock option (NQSO) structures used by peers like Mesoblast or Rocket Pharmaceuticals.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if and when these options are exercised in the future.
• The Chief Commercial Officer is incentivized to increase the company's market valuation above the $29.36 strike price.

Next Steps

• First vesting cliff to occur on the first anniversary of the first day of the month following the grant date.
• Monthly vesting of the remaining 75% over the subsequent 36 months.

Key Dates

Recommendation

This is a routine Form 4 filing for executive compensation. While it shows management alignment, it does not provide new material information regarding the company's clinical progress or financial stability that would warrant a change in investment rating.

Keywords

Capricor Therapeutics, CAPR, Stock Options, Executive Compensation, Insider Trading, Biotechnology, Chief Commercial Officer